With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
The latest business developments from across Asia by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising
potential for other companies to move into export markets.
UK and Singapore Endorse Innovation and Trade Agreement
The Science and Technology Facilities Council (STFC) UK and Singapore Space and Technology Limited (SSTL) have signed a new partnership agreement reinforcing their commitment to jointly support investment and trade between the two nations, following instigation of an initial agreement in February 2022.
The new signing, conducted at the Global Space and Technology Convention 2023 in Singapore, aims to provide space tech start-ups with the tools, expertise and access they need to thrive on a global scale.
Last year the joint agreement resulted in several initiatives supported by the former Department of International Trade (DIT), including:
• commercial collaborations with In-Space Missions to organise the Asia Pacifi c rideshare mission
• the formation of a UK-Singapore joint venture between Singaporean start-up Navigate Commodities and UK based Earth-i
It has also built on several other successful collaborations between STFC and Singaporean organisations including the £10 million jointly funded Speqtre mission which is led by STFC’s RAL Space in the UK and SpeQtral in Singapore.
Examples of areas that future collaborations will focus on include:
• reciprocal access to Asia Pacifi c and European venture capital ecosystems for potential investment
• reciprocal access to test facilities and resources, supportive infrastructure and national laboratories
• UK-based space tech start-ups to be considered for SSTL’s Space Accelerator Programme
• Singapore-based space tech start-ups to be considered for the European Space Agency Business Incubation Centre United Kingdom (ESA BIC UK)
• access for Singapore-based space tech start-ups to the European Space Agency (ESA) network
• developing collaborations between UK-based and Singapore- based universities for knowledge transfer and capability building
STFC manages and co-funds the ESA BIC UK, in partnership with the UK Space Agency, ESA Space Solutions and the University of Leicester. It is part of the world’s largest business incubation programme for space tech start-ups.
STFC Executive Director for Business and Innovation, Paul Vernon, said: “Space is one of the most innovative and fastest growing industrial sectors in the world. However, for a start- up business, using space technologies to create new and profi table products or services can be a challenging process.
“Successful start-ups are essential to our future prosperity, binging tangible benefi ts to our economy and society. STFC has a fi rm commitment to provide the best environment possible for them to innovate and grow, and collaboration is key.
“There has never been a more exciting time for a business to get involved in the space industry and the opportunities it can bring. I look forward to our continued partnership with Singapore Space and Technology Limited as we support our space tech start-ups in their mission to innovate, fl ourish and succeed in global markets.
British High Commissioner to Singapore, Kara Owen, said: “The UK space sector is valued at £16.5bn and is a fast growing and important part of our economy. We are investing to enable scientists and engineers to participate in some of the world’s most important space missions.
Key Appointments Set to Drive Business Growth
In mid-December 2022, Hamamatsu Photonics, a prominent provider of cutting-edge photonics technology, announced the appointment of Mr Tadashi Maruno as the Representative Director and President during the company’s 75th ordinary meeting.
Having spent four decades with Hamamatsu Photonics, Mr Tadashi Maruno previously held the position of Representative Director and Senior Managing Executive Offi ce before assuming his current role. He has also served as the Manager (2014) and later as Division Director (2017) of the System Division, which oversees all aspects of Manufacturing and Semiconductor support systems, Photometry systems, as well as Life Science & Medical systems.
Tadashi Maruno
“We are looking forward to working with Mr Tadashi Maruno and the new Management team as they navigate us toward further success,” said Max Skoglund, Hamamatsu Photonics Europe Managing Director.
Mr Akira Hiruma, who served as Hamamatsu’s Representative Director and President for 13 years, has now been appointed as the Representative Director and Chairman of the company.
More information online:
ilmt.co/PL/k1Vj 59829pr@reply-direct.com
The signing event, left to right: Harshbir Sangha (Director of Growth, UK Space Agency), H.E. Kara Owen (High Commissioner, British High Commission), Amy Farrington (Head of Business Incubation, STFC), Lynette Tan (Chief Executive, SSTL) and Johnathan Hung (Executive Chairman, SSTL). Credit: STFC
“To get truly successful though, our sector needs to optimise its international connections. Our space partnership with Singapore is a priority for our sector so working with SSTL, the leading space organisation in Southeast Asia, makes absolute sense.
“This agreement will make a very practical and multi-year contribution to building space sectors in both countries. It will provide practical support, access to funding, to testing and other facilities and will deliver more commercial partnerships and joint innovation. I congratulate STFC and SSTL putting in place such a substantive and important partnership.”
More information online:
ilmt.co/PL/m1zq and
ilmt.co/PL/BKOk
59924pr@reply-direct.com
MOU Marks Way for Joint Venture
Global clinical trial laboratory service provider Cerba Research has signed a Memorandum of Understanding with Teddy Clinical Research Laboratory, to lay the foundation for an in-depth discussion towards the creation of a Joint Venture (JV).
The two companies, along with Cerba Research’s specialty virology subsidiary Viroclinics-DDL, have had a long track record in collaborative projects since 2012 and the intended JV will leverage Teddy’s strong reputation within mainland China for high quality central lab solutions, backed with over 12 years of clinical trial experience, with Cerba Research’s market-leading scientifi c expertise & technical capabilities spanning immuno-oncology, cell & gene therapy, vaccines and infectious disease research drug development.
The formal signing ceremony in February took place at Cerba Research’s Ghent offi ce, led by Mario Papillon, CEO of Cerba Research, and Xu Yi, CEO of Teddy Lab, on behalf of their respective organisations.
The event was also attended by representatives of the Wuxi Government and members of the executive team for both parties.
Mario Papillon, CEO of Cerba Research commented: “This MoU is an important milestone with Teddy Lab which demonstrates our commitment to expand our footprint into new geographic territories and to best support our global biopharma customers in their evolving needs. We are delighted to deepen our partnership with Teddy Lab that will enable us to build on existing knowledge and increase services within China to support customers with their global drug development programmes.
“Teddy Lab has been a trusted partner for many years and mirrors our commitment to high-quality, patient-centric solutions. We are honoured by Wuxi’s support and their dedication to pave the way for future and stronger cooperation.”
XU Yi, CEO Teddy Clinical Research Laboratory, said: “With today’s MoU signing celebration, Cerba Research and Teddy Lab show their will to serve as a bridge from overseas markets to China and vice versa. It is aligned with Teddy Lab’s strategy and complementary with Teddy Lab’s geographical presence. We are impressed to see Cerba Research’s success in recent years and confi dent in the future outcome.
“Teddy Lab also reached multiple milestones in the past 5 years. Particularly, Teddy Lab Wuxi set up in 2020 with the great help of Wuxi Government. During the pandemic, Teddy Lab Wuxi have supported over dozens of COVID drug or vaccine clinical trials, many of which are working closely with Cerba Research and as a result, multiple candidates have been approved under emergency use in different countries.
“I am proud and humble to say that, together, Cerba Research and Teddy Lab have contributed greatly to the fi ght against the pandemic. We look forward to deepening our collaboration in next decades and contributing more to state-of-the-art clinical trials for effi cient medicine to patients’ benefi ts throughout the world.”
More information online:
ilmt.co/PL/K6ZA 59925pr@reply-direct.com
Business
Opportunities Asia
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
